200 related articles for article (PubMed ID: 27356024)
1. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management.
Owens GM
Am J Manag Care; 2016 Jun; 22(6 Suppl):s151-8. PubMed ID: 27356024
[TBL] [Abstract][Full Text] [Related]
2. Managed care aspects of managing multiple sclerosis.
Owens GM
Am J Manag Care; 2013 Nov; 19(16 Suppl):s307-12. PubMed ID: 24494620
[TBL] [Abstract][Full Text] [Related]
3. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
Bandari DS; Sternaman D; Chan T; Prostko CR; Sapir T
J Manag Care Pharm; 2012; 18(9):1-17. PubMed ID: 23206263
[TBL] [Abstract][Full Text] [Related]
4. Managed approaches to multiple sclerosis in special populations.
Sperandeo K; Nogrady L; Moreo K; Prostko CR
J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
[TBL] [Abstract][Full Text] [Related]
5. Impact on healthcare resource utilization of multiple sclerosis in Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
[TBL] [Abstract][Full Text] [Related]
7. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
Rotstein Z; Hazan R; Barak Y; Achiron A
Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
[TBL] [Abstract][Full Text] [Related]
8. Reconsidering the economic value of multiple sclerosis therapies.
Shih T; Wakeford C; Meletiche D; Sussell J; Chung A; Liu Y; Shim JJ; Lakdawalla D
Am J Manag Care; 2016 Nov; 22(11):e368-e374. PubMed ID: 27849348
[TBL] [Abstract][Full Text] [Related]
9. Health economic issues in MS.
Kobelt G
Int MS J; 2006 Jan; 13(1):17-26, 16. PubMed ID: 16420781
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.
Kendrick M; Johnson KI
Pharmacoeconomics; 2000 Jul; 18(1):45-53. PubMed ID: 11010603
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of disease-modifying therapies in multiple sclerosis.
Manouchehrinia A; Constantinescu CS
Curr Neurol Neurosci Rep; 2012 Oct; 12(5):592-600. PubMed ID: 22782520
[TBL] [Abstract][Full Text] [Related]
12. Brain health: time matters in multiple sclerosis.
Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
14. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
15. There is much to be learnt about the costs of multiple sclerosis in Latin America.
Romano M; Machnicki G; Rojas JI; Frider N; Correale J
Arq Neuropsiquiatr; 2013 Aug; 71(8):549-55. PubMed ID: 23982015
[TBL] [Abstract][Full Text] [Related]
16. Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O; Calleja-Hernández MA; Meca-Lallana J; Oreja-Guevara C; Polanco A; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):321-333. PubMed ID: 28726515
[TBL] [Abstract][Full Text] [Related]
17. The cost of multiple sclerosis in Australia.
Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
[TBL] [Abstract][Full Text] [Related]
18. Managed care aspects of managing multiple sclerosis.
Mathis AS
Am J Manag Care; 2013 Feb; 19(2 Suppl):S28-34. PubMed ID: 23544718
[TBL] [Abstract][Full Text] [Related]
19. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.
; Rieckmann P; Centonze D; Elovaara I; Giovannoni G; Havrdová E; Kesselring J; Kobelt G; Langdon D; Morrow SA; Oreja-Guevara C; Schippling S; Thalheim C; Thompson H; Vermersch P; Aston K; Bauer B; Demory C; Giambastiani MP; Hlavacova J; Nouvet-Gire J; Pepper G; Pontaga M; Rogan E; Rogalski C; van Galen P; Ben-Amor AF
Mult Scler Relat Disord; 2018 Jan; 19():153-160. PubMed ID: 29241142
[TBL] [Abstract][Full Text] [Related]
20. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
